top of page
Pipeline
Team
Contact
First-in-class
Bach1 inhibitors with
transformative potential
as oral therapy for patients with
sickle cell disease (SCD)
and beyond
Growing Our Vision
PIPELINE
OUR TEAM
GET IN TOUCH
WEBSITE UNDER DEVELOPMENT
Reach out for more info
CONTACT US
bottom of page